Longeveron Inc.
A clinical-stage biotech that turns young adults' bone-marrow stem cells into an injectable therapy, called Lomecel-B, being studied for aging-related conditions like frailty, Alzheimer's disease and a rare childhood heart defect. The company was founded in 2014 and spun out of the University of Miami's stem-cell institute. Its name blends "longevity" with "ever on"—a nod to its mission of helping people live longer, healthier lives.
Granted 462.9K · Bought 156.4K · Sold 165.3K
Granted 1.02M · Bought 1.8K
Granted 900.0K
Granted 843.8K
Granted 638.0K
Granted 566.8K · Bought 11.8K
Granted 631.5K · Bought 10.6K
Granted 106.5K · Bought 158.2K · Sold 42.5K
Bought 1.0K
Granted 50.0K
Granted 76.5K
Granted 70.0K
Granted 69.0K
Granted 45.5K · Bought 21.8K · Sold 1.3K
Granted 40.0K · Bought 5.0K · Sold 60.5K
Granted 36.0K
Granted 36.0K
Granted 36.0K
Granted 33.0K
Granted 33.0K
Granted 23.5K
Granted 5.0K · Bought 10.0K
Bought 5.0K
Granted 5.0K
Granted 152.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Soffer Donald MDirector · 3 transactions | — | 13.72Mas of May 2022 | — | — | — |
| Hare JoshuaChief Scientific Officer, Director, 10% owner · 16 transactions | — | 1.61M | 462.9K | 156.4K | 165.3K |
| Lehr Paul TGeneral Counsel, Secretary · 29 transactions | — | 861.4K | 1.02M | 1.8K | — |
| Willard Stephen HChief Executive Officer · 5 transactions | — | 789.7K | 900.0K | — | — |
| Agafonova NataliyaChief Medical Officer · 17 transactions | — | 716.9K | 843.8K | — | — |
| Blass DevinCTO & SVP of CMC · 7 transactions | — | 711.7K | 638.0K | — | — |
| Locklear LisaChief Financial Officer · 18 transactions | — | 465.7K | 566.8K | 11.8K | — |
| Hashad Mohamed Wa'el AhmedChief Executive Officer · 16 transactions | — | 420.9Kas of Jul 2025 | 631.5K | 10.6K | — |
| Soffer RockDirector · 17 transactions | — | 262.0K | 106.5K | 158.2K | 42.5K |
| Green GeoffCEO · 4 transactions | -26.7% | 133.9Kas of Apr 2022 | — | 1.0K | — |
| Powell James NathanielChief Executive Officer · 3 transactions | — | 125.6K | 50.0K | — | — |
| Ungaro UrsulaDirector · 3 transactions | — | 77.0K | 76.5K | — | — |
| Paletta George A. Jr.Director · 2 transactions | — | 70.0K | 70.0K | — | — |
| Hajjar Roger JosephDirector · 3 transactions | — | 69.0K | 69.0K | — | — |
| Baluch KhosoDirector · 8 transactions | — | 52.5Kas of Aug 2025 | 45.5K | 21.8K | 1.3K |
| Clavijo JamesCFO and Treasurer · 16 transactions | -49.5% | 47.3Kas of Jun 2023 | 40.0K | 5.0K | 60.5K |
| Ascheim DeborahDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
| Cann Leah RushDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
| Desai Arjun JJDirector · 1 transaction | — | 36.0K | 36.0K | — | — |
| Kender Richard NDirector · 2 transactions | — | 33.0Kas of Jul 2025 | 33.0K | — | — |
| Motwani Neha J.Director · 2 transactions | — | 33.0Kas of Jul 2025 | 33.0K | — | — |
| Hare Neil EDirector · 1 transaction | — | 30.2Kas of Aug 2024 | 23.5K | — | — |
| Pfeffer JeffreyDirector · 2 transactions | — | 15.0Kas of Dec 2023 | 5.0K | 10.0K | — |
| Ross CathyDirector · 1 transaction | — | 10.0Kas of Jan 2024 | — | 5.0K | — |
| Girolamo Todd CDirector · 1 transaction | — | 5.0Kas of Feb 2022 | 5.0K | — | — |
| DS Med LLC10% owner · 2 transactions | -100% | 0as of May 2022 | — | — | — |
| Min Kwan-Hong ChristopherChief Medical Officer · 3 transactions | — | 0as of Apr 2022 | 152.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +112.1K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.